Rheumatoid arthritis is a crippling condition affecting 1.3 million people. To date, the standard of care has been to head ...

med.uoeh-u.ac.jp Biological agents targeting tumour necrosis factor (TNF) have revolutionised the treatment of rheumatoid arthritis (RA) and clinical remission has become a realistic treatment goal.

Leflunomide, like methotrexate, has a role in RA treatment... As the goal of RA treatment is to induce disease remission, the current agents of choice are biologic agents that target specific ...

The study suggests that this gut bacterium may drive the immune response leading to RA in people who are genetically or ...

lumc.nl In rheumatoid arthritis (RA), it is becoming common to attempt to taper or stop medication, aiming for sustained drug-free remission (SDFR). Autoantibody seropositivity is a poor prognostic ...

Timely escalation to second-line disease-modifying drugs after treat-to-target methotrexate failure may not prevent the development of difficult-to-treat rheumatoid arthritis. Early treatment ...

Monoclonal antibodies are novel therapeutic agents used with great success in the treatment of rheumatoid arthritis (RA). Different parts of the immune system have been targeted by monoclonal ...

RA treatment aims to decrease inflammation, which decreases symptoms (pain/discomfort and stiffness), and lessens the risk of joint damage. By limiting joint damage, disability is reduced. The primary ...

Here, we analyse whether disease activity in the early stages of RA could influence progression to a D2T RA under real-life conditions. Other clinical and treatment-related factors were also analysed.

That's the goal. And if we don't achieve that ... Like most other chronic inflammatory conditions, whether it's rheumatoid arthritis or Crohn's disease, it's a challenge. Once the body has ...

among patients with early rheumatoid arthritis (RA) are predictive of a reduced response to methotrexate (MTX), according to study findings published in Rheumatology (Oxford). While MTX is a standard ...

Longer duration of a flare was associated with changes in disease-modifying therapy. It's essential to work with your healthcare provider to monitor your symptoms and tweak your treatment plan ...